Introduction
Predicting the prognosis of individual heart failure (HF) patients is vital to individualize treatment. At present, many classification models for HF have been proposed. In these models, demographics (age and sex), severity of the disease [New York Heart Association (NYHA) classification], renal insufficiency, blood pressure, diabetes, sodium, blood urea, left ventricular ejection fraction (LVEF) and treatment are among the most frequently used parameters for HF risk stratification.
1,2 However, these parameters, alone or combined, either fall short of accurate prediction or are too elaborate to be widely clinically implemented. 3 -5 Besides, predictors such as NYHA class involve subjective clinical interpretation which limits the comparability between different individuals and institutes. Therefore, additional simple and objective measures to stratify HF patients according to their risk are needed. Biomarkers, such as natriuretic peptides (markers of myocardial stretch), high-sensitivity cardiac troponins (markers of myocyte injury) or ST2 (surrogate of fibrosis) have shown value to refine risk prediction in HF.
3,6 -9 They offer quickly accessible and operator-independent indicators of risk, yet despite their added value, prognostication has considerable residual uncertainty and in most cases additional tools are required for clinically actionable risk stratification.
MicroRNAs (miRNAs) are small non-coding RNAs that influence protein translation and represent a level of biologic regulation that was essentially unknown a decade ago. 10 As a result of their stable expression in blood plasma, 11 circulating miRNAs have gained much interest as potential non-peptide, genomic biomarkers. Several small-scale studies reported the discovery of a number of circulating miRNAs, among them miR-423-5p and miR-320a, that may play a crucial role in the pathogenesis of HF. 12, 13 In a recent study, muscle-related circulating miRNAs (so-called 'myomiRs') seemed dynamically regulated in a small group of different types of HF patients.
14 Among these myomiRs, circulating miR-208a-3p and miR-499a-5p were shown to be upregulated in patients with myocardial damage. 15 Although these studies suggest a potentially important role for these miRNAs as HF biomarkers, it is still unknown whether they are useful for prediction of the future course of the disease. There are concerns about these circulating miRNAs as biomarkers for HF since large differences in miRNA profiles are found among the many published studies, 16 raising doubt about the replicability of findings between techniques and cohorts. On the other hand, in a non-HF setting, some studies have been able to find replicable results, suggesting a more positive outlook on miRNAs as biomarkers. 17 In many cases, the lack of replicability might not reflect bad properties of miRNAs as biomarkers, but rather a challenge in the methods of miRNA quantification and data handling.
In order to avoid excessive noise and determine the true value of miRNA biomarkers, investigations in larger cohorts using standardized methods of measurement are needed. Therefore, in this study we investigated the predictive value, alone or in combination with conventional predictors, of 12 circulating miRNAs that are known to be cardiac enriched or have been previously identified in relation to HF. We studied them in a large and diverse . sample of HF patients taken from two independent cohorts using standardized methods for the measurements by quantitative polymerase chain reaction (qPCR) and analysed the data according to a self-developed, pre-specified algorithm to minimize noise introduced by inaccurate results.
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Methods
Study population Cohort I (Barcelona)
This cohort was previously used in HF risk stratification studies. 3, 19 Between August 2006 and June 2011, ambulatory patients treated at a multidisciplinary HF unit were consecutively included in the study in an outpatient setting of a tertiary hospital. The majority of the patients were referred from cardiology (70%) and internal medicine (15%), and the principal referral criterion was HF irrespective of aetiology (at least one HF hospitalization and/or reduced LVEF). 20 Blood samples were obtained by venipuncture between 9:00 a.m. and noon during routine ambulatory visits as described in more detail in the supplemental Methods. None of the patients used heparin therapy at the time of their blood collection. Left ventricular ejection fraction was measured using Simpson's rule. All the participants provided written informed consent, and the local ethics committee (Clinical Investigation Ethics Committee, Hospital Universitari Germans Trias i Pujol, Badalona, Spain) approved the study. All the study procedures were in accord with the ethical standards outlined in the 1975 Declaration of Helsinki, as revised in 1983.
Cohort II (Detroit)
The study was approved by the Henry Ford Hospital Institutional Review Board and all patient participants gave written informed consent. All the study procedures were in accord with the ethical standards outlined in the 1975 Declaration of Helsinki, as revised in 1983. The Henry Ford Heart Failure Pharmacogenomic Registry (cohort II) is a prospective, observational, cohort study which enrolled 1750 HF patients between 2007 and 2015. Patients whose health care was administered by our covered entity (Health Alliance Plan) and who met enrollment criteria were recruited and prospectively enrolled. Inclusion criteria included age ≥ 18 years and symptomatic HF meeting Framingham definition. Exclusion criteria included end-stage renal disease (on dialysis) or inability to provide written informed consent. Patients were characterized at baseline in terms of their HF symptoms, quality of life, and co-morbid conditions, and blood samples were collected for genetic and biomarker analysis as described in more detail in the supplemental Methods. None of the patients used heparin therapy at the time of their blood collection. Patients were required to have had an assessment of their ejection fraction prior to study entry (most often echocardiography). Echocardiograms were clinical studies and the results were abstracted from the electronic health record. Our clinical echocardiography laboratory follows American Society of Echocardiography guidelines. Ejection fraction assessment in the Henry Ford Hospital lab is performed using modified Simpson formula for biplane ejection fraction estimation using the two-and four-chamber views. Among the total cohort, 1150 patients had an LVEF <50% at diagnosis [HF with reduced ejection fraction (HFrEF) subgroup] while 600 subjects had a LVEF ≥50% [HF with preserved ejection fraction (HFpEF) subgroup]. From this cohort, the first included 1369 patients were used for miRNA measurement and analysis.
Follow-up and outcomes
Further information on follow-up and outcomes of both cohorts are described in the supplemental Methods.
Measurement of circulating miRNAs
After RNA extraction, miRNAs were measured in plasma as extensively described following the minimum information for publication of real-time qPCR experiments (MIQE) guidelines in the supplemental Methods. MiR-622, miR-1254, miR-423-5p, 13 miR-22-3p, and miR-320a 12 were selected based on previous studies that showed elevated levels of these circulating miRNAs in HF patients. MiR-378a-3p and miR-345-5p were selected since these are myocardial enriched, 21 while miR-133a-3p, miR-133b, miR-208a-3p and miR-499a-5p are myocardial miRNAs of which the latter two are heart-specific and are released upon cardiac damage. 15, 22 MiR-1306-5p was chosen since we had identified it as a candidate in the pressure loaded heart. 23 In a previous study, we showed that for normalization endogenous miRNAs are preferred over normalization with a spike-in (e.g. Cel39 spike-in) or small RNAs (e.g. RNU6B). 24 Therefore, miR-486-5p was used for normalization of the data since this miRNA was abundant and showed a stable expression as extensively described in the supplemental Methods. To investigate the influence of having only one normalizer, we repeated the analysis after adding the most stable and abundant miRNA out of our panel of miRNAs, miR-320a, to the normalization panel as described in more detail in the supplemental Methods.
Quality control of miRNA qPCR measurements
QPCR of circulating miRNAs in plasma are sensitive to false or inaccurate signals, which is partly explained by the often low concentrations of miRNAs in plasma. 25 Therefore, we used a quality assessment algorithm to ensure the validity of each measurement. This procedure is described extensively elsewhere. 18 In brief, we distinguished three groups of measurements: 'valid', 'invalid', or 'undetectable' (signal too low). In case of undetectable measurement, the sample was set to a low value, which was based on the qPCR experiment parameters. If the measurement did not pass the quality controls of the algorithm, it defined as 'invalid'. When a measurement was considered invalid, it was taken into the analysis as missing at random and was therefore imputed using multiple imputations. If the measurement passed all the quality checks, it was marked as 'valid' and was included in the analysis.
Circulating peptide biomarkers
Peptide biomarkers [e.g. N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T] were measured as described more extensively in the supplemental Methods.
Statistical analysis
Baseline characteristics of the study population were presented as mean ± standard deviation (SD), or median [interquartile range (IQR)] for continuous variables, and absolute number with percentages for categorical variables. Both cohorts had less than 3% missing data among all clinical variables. We used multiple imputation for missing values of the following variables: cohort I: body mass index (BMI) (n = 13), duration of HF (n = 1), sodium (n = 7), creatinine (n = (n = 2); cohort II: age (n = 1), BMI (n = 29), LVEF (n = 5), sodium (n = 9), creatinine (n = 9), haemoglobin (n = 10).
Raw qPCR data were log-transformed and normalized using miR-486-5p. Cox proportional hazard analysis was used to analyse the association of the candidate miRNAs with the risk for HF-related morbidity and mortality as defined previously. The C-statistic (C-stat) was used to quantify the discriminative ability between HF patients who reached the endpoints and those who did not. C-statistics were corrected for optimism by bootstrapping (n = 100). Analyses were performed by IBM SPSS Statistics version 22 and statistical environment R studio version 0.98.1103.
The primary endpoint for this study comprised the composite of all-cause mortality and HF hospitalization. Secondary endpoints were all-cause mortality and HF hospitalization alone.
First, we analyzed the association of the individual miRNAs with the risk for the outcomes univariately. A panel of miRNAs was established from miRNAs that showed significant association with the primary outcome, HF-related morbidity and mortality, in both cohorts.
Second, this panel was used in addition to established objectively measurable risk factors, sex, age, serum creatinine, haemoglobin level and NT-proBNP level. Several models were built to analyse the discriminating power of each of those models on HF-related morbidity and mortality. Since we aim to generate easy-to-use operator independent risk prediction tools, we intentionally did not use proven risk indicators that are subjective or more difficult to obtain such as NYHA class or ejection fraction. Model 1 only contained age (continuous) and sex; model 2 only contained haemoglobin (continuous) and creatinine (continuous); model 3 only contained NT-proBNP (continuous); and model 4a-d contained extended models with the addition of the discriminating miRNAs panel.
Results
Description of cohorts
Patient characteristics are shown in Table 1 . Cohort I (Barcelona) included 834 patients at baseline with a mean age of 68 ± 13 years, and 71% were male. The mean LVEF was 35 ± 14%, and the main aetiology of HF was ischaemic heart disease (52%). The population mainly consisted of cases with HFrEF (84%). During a mean follow-up of 3.8 years, 183 (22%) patients were hospitalized due to HF, and 344 (41%) participants died.
In cohort II (Detroit), miRNA levels were measured in 1369 HF patients at baseline with a mean age of 69 ± 12 years, and 58% were male. The population included both cases with HFrEF (59%) and HFpEF (41%). During a mean follow-up of 1.9 years, 450 (33%) patients were hospitalized due to HF, and 222 (16%) participants died. The baseline characteristics stratified by outcome are shown in the Supplementary material online, Table S1 . Values are expressed as mean ± SD or n (%), unless indicated otherwise. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
more often 'valid' in cohort I compared to cohort II. MiR-208a-3p was 'valid' in only one case (0.1%) in cohort I, and in cohort II it was 'valid' in only 30 cases (2%). Nevertheless, it was 'undetectable' in the vast majority of cases in both cohorts indicating that miR-208a-3p was reliably below the limit of detection in the vast majority of samples. For miR-499a-5p, we found similar numbers with a slightly higher 'valid' rate of 113 cases (14%) in cohort I and 135 cases (10%) in cohort II. Low expression of these miRNAs is not unexpected, since these myomiRs are known to be released only after myocardial damage, although minor myocardial damage may be expected at an appreciable rate in HF patients. Notably, the 'valid' rate for miR-133b was much higher with 82% of the cases in cohort I, while it was only 'valid' in 8% of the cases in cohort II (Supplementary material online, Figure 1 and Supplementary material online, Table S3A ). Figure 2 shows the difference in the risk of reaching the primary endpoint for patients in different quartiles of miR-1254 and miR1306-5p levels in cohort I. Adding miR-320a to the normalization panel did not change the above results (data not shown). For all-cause mortality, four miRNAs were predictive and emerged in both cohorts: miR-1254 with a HR of 1.19 (95% CI Figure 1 Univariate Cox regression analysis for the combined endpoint of all-cause mortality and heart failure hospitalization. Hazard ratios (bars) with 95% confidence intervals (CI) (whiskers) per log-unit increase of miRNA expression for the combined endpoint (all-cause mortality and heart failure hospitalization). For the exact values of the univariate Cox regression analysis and the outcomes all-cause mortality and heart failure hospitalization only, see the Supplementary material online, Table S3B ).
For HF hospitalization, none of the miRNAs appeared significantly predictive in both cohorts (Supplementary material online, Table S3C ). Correlations between all microRNAs can be found in the Supplementary material online, Table S4 .
Predictive value of circulating miRNAs on outcomes in multivariate analysis
We next assessed whether the addition of circulating miRNAs improved prognostication on top of established objectively measurable prognosticators. We analysed models with increasing complexity by adding different biomarkers to a simple model of only clinical parameters.
For the primary combined endpoint ( Table S5 ). We then added miRNA markers when they were significantly associated with the risk of reaching the combined endpoint in both cohort I and II as analysed above. Therefore, the multimarker panel of miRNAs comprised miR-1254 and miR-1306-5p. This panel of miRNAs alone predicted the combined endpoint with a c-stat of 0.54 (95% CI 0.51-0.58) in cohort I and a c-stat of 0.56 (95% CI 0.52-0.59) in cohort II. Addition of the miRNA panel to all previous described predictors (model 4d: age, sex, haemoglobin, creatinine, NT-proBNP and miRNAs) did not improve c-stat.
The endpoint outcome of all-cause mortality and HF hospitalization yielded comparable results (Supplementary material online, Table S5 ). The discriminative ability of all single miRNAs are provided in the Supplementary material online, Table S6 .
Figure 2
Kaplan-Meier survival curves for the primary endpoint stratified for quartiles of miRNA expression. Kaplan-Meier survival curves for the primary endpoint of all-cause mortality and hospitalization for heart failure in the four quartiles of (A) miR-1254 levels and (B) miR-1306-5p levels (Q1 lowest quartile, Q4 highest quartile) in cohort I. Table S5 .
Discussion
In this study, we investigated the incremental value of 12 circulating miRNAs as potential biomarkers for the prognostication of HF patients in addition to established risk stratifiers. Our main finding is that higher levels of circulating miR-1254 and miR-1306-5p were significantly associated with the risk of reaching the combined endpoint and that higher miR-1254, miR-133b, miR-622 and . miR-208a-3p significantly associated with all-cause mortality in two large independent cohorts of different types of HF patients. The replication of these associations in both cohorts suggests that these miRNAs are particularly relevant for disease progression in HF. However, these circulating miRNAs do not add substantial prognostic power to existing risk prediction models. So while these are likely to be important targets for additional research into the biologic mechanisms underlying disease progression, they are unlikely to become clinical biomarkers. This lack of incremental predictive information may be due to the high rate of technical drop-out resulting in an appreciable loss of data points, or, more likely, that variations captured in these circulating miRNAs are already reflected in contemporary clinical and biomarker data. Many of the miRNAs we validated have a biologically plausible explanation for association with HF outcomes. MiR-133a-3p and miR-133b are among the most extensively described miRNAs and are found to be abundantly expressed in all types of muscle. In contrast to miR-133a-3p, which is also abundant in cardiac muscle, miR-133b is particularly found in skeletal muscle tissue and is involved in skeletal muscle cell development as well as in neuromuscular synapse development and maintenance. 26 -28 Therefore, the association of miR-133b with the risk of mortality may reflect muscle degradation in patients with a poor nutritional status. There are little data regarding the function of miR-1254 and miR-622. Both were discovered to be upregulated in HF by Tijsen et al. 13 and our findings indicate a consistent and strong association with the risk for mortality and for miR-1254 also for HF morbidity. MiR-1254 is transcribed together with CCAR1 (cell division and apoptosis regulator protein 1). While this protein is involved in transcriptional regulation and apoptosis, it has not been associated with cardiovascular disease. Further functional investigation is needed to clarify the biological role of miR-1254 in HF.
MiR-1306-5p was discovered to be associated with HF in the study of van Boven et al., 23 who showed that this miRNA is released from the myocardium. This miRNA lies within the DGCR8 gene that codes for a protein that is required for miRNA processing by binding to Drosha enzyme. This protein has never been associated with cardiovascular disease. MiR-1306 has never been described in HF before this study and has no known function to date.
Role of heart-specific circulating miRNAs
Since in HF cardiac injury markers are also highly prognostic, 9,29 -31 we expected that circulating miRs-208a-3p and -499a-5p would have robust prognostic power as these miRNAs are heart-specific and are upregulated upon cardiac damage.
1 Measurements of miR-208a-3p and miR-499a-5p were below the limit of detection in most samples, which was usually concordant in duplicates so that this seems reliably measured. The small number of valid measurements has obviously lowered the power of these miRNAs and hence their ability to add to the prognostication. Nevertheless, despite very small numbers of measurements, miR-208a-3p still emerged as prognostic in a number of analyses. This suggests that we currently underestimate their prognostic role and that with improved technologies to more reliably and accurately measure such very low abundance, yet heart-specific miRNAs, their prognostic power may be much better appreciated.
Strengths and limitations
In this study, two very distinct populations were compared. There were substantial differences in ethnicity, age, BMI, and type of HF HFpEF) and both cohorts used different criteria for HF (cohort I used European Society of Cardiology criteria and cohort II used Framingham criteria). While this could potentially influence the association between miRNAs and the risk for the outcomes, our modelling adjusted for several known important predictors of outcome, and in fact the validation of miRNA associations across such a diverse setting underscores the validity of our findings. Indeed, despite the marked clinical differences across cohorts, we were able to show that miR-1254 and miR-1306-5p were associated with the risk of the combined endpoint and miR-133b, miR-622 and miR-208a-3p with the risk of mortality in both cohorts; a major strength of the approach which indicates the results are robust across different populations. Strikingly, in a separate study where HF patients were prospectively sampled sequentially, the same method we used here also identified miR-1254 and miR-1306-5p as prognosticators of all-cause mortality and HF hospitalization. This further underlines the replicability of our findings. 23 In this study, we used HF-related miRNAs that were identified previously. Therefore, it cannot be ruled out that some miRNA biomarkers for HF mortality and morbidity prediction are still to be identified.
Between the two cohorts we found differences in the proportion of miRNAs that could be reliably measured after aforementioned quality controls. These differences might be explained by population differences. The fact that cohort I had much more HFrEF and much less NYHA class I patients than cohort II could have caused this difference. On the other hand, while both studies used standard methods for sample collection, this could reflect differences in RNA isolation or the reverse transcriptase reaction between cohorts. The fact, however, that highly consistent results were found in this study indicates that these differences in the proportion of reliable measurements were unlikely to have a large influence on our findings. It also underscores some of the current limitations of miRNA measurement, which could be sensitive to modest variation in sample collection and handling.
For normalization of the data, we used miR-486-5p. However, one might argue that normalization with only one miRNA with a relatively high M-value might be suboptimal. On the other hand, because adding miR-320a to the normalization panel did not change the results, it is unlikely that this was of large influence on the conclusions made in this study. MiR-486-5p may reflect the amount of erythrocytes in the sample, since it is mainly found in erythrocytes; however, miR-486-5p may also stem from multiple other sources. In our cohorts, miR-486-5p showed a weak correlation (Pearson's r = 0.098 and 0.162 in cohort I and II, respectively) with haemoglobin. Levels of miR-486-5p in plasma may reflect handling and processing of the samples, explaining why correcting for this miRNA reduced random variability in the two cohorts.
Indeed, inconsistent findings between studies have been a problem in circulating miRNA studies. Besides sensitivity to processes as noted above, another reason for these inconsistencies is the fact that the concentration of many circulating miRNAs is often very low. Therefore, reliable measurement of these low concentrations, close to the detection limit of the qPCR method, poses important challenges. In our study, we classified miRNAs below the detection limit as 'undetectable'. However, one could argue that whether a result is below the detection limit or not, is dependent on the method of quantification. Therefore, we compared our method of quantification (qScript™ microRNA cDNA Synthesis Kit) to quantification using Taqman™ probes, and found similar numbers of 'undetectable' results (Supplementary material online, Figure  S1 ). Also, as the qPCR method can by definition not distinguish flawed experiments from undetectably low concentrations, some data points will have to be designated as 'invalid', perhaps errantly. However, this study shows that the use of this stringent algorithm sufficiently reduces noise to allow robust signals to emerge and be replicated. Therefore, we propose to use this data handling algorithm as a new standard for circulating miRNA measurements.
Conclusion
In our study, we found that miR-1254 and miR-1306-5p were significantly associated with the risk of the combined endpoint (mortality and HF hospitalization) and miR-133b, miR-622 and miR-208a-3p were associated with mortality only in two separate, large and diverse cohorts of HF patients. However, measurement of circulating miRNAs did not improve prognostication when combined with established risk predictors such as peptide biomarkers (NT-proBNP). The combination of the large sample size, the consistency of findings in two heterogeneous cohorts, and the use of a stringent qPCR data handling algorithm to ensure robust and valid results, makes this a unique study which provides an important step toward miRNA risk profiling and improved risk prediction in HF.
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